Scotland’s cost-effectiveness body has rejected regular NHS funding for Vertex’s cystic fibrosis drugs Orkambi and Symkevi because of concerns about whether their high costs justify uncerta
A group of parents in the UK have taken matters into their own hands in an effort to get their children access to Orkambi, the cystic fibrosis drug at the centre of a three and a half year
